Insights

Acquisition Momentum Terns is a clinical-stage biopharma with a headline market event: a potential $6.7B acquisition by Merck reported in 2026, signaling strong strategic interest and potential near-term licensing or partnership opportunities for large pharma.

Leukemia Focus Analysts view Terns' leukemia program as a potential multibillion-dollar asset that could compete with Scemblix, indicating a high-opportunity sales target for hematology/oncology BD teams and potential co-development or licensing discussions.

GLP-1 Obesity Potential Terns is developing GLP-1 based therapies for obesity and diabetes, a hot market segment with ongoing competition. This presents a path for strategic partnerships, joint development, or out-licensing of GLP-1 programs or related assets.

Strategic Financing Recent leadership movement and large-scale financing imply active corporate development and capital-raising activity, suggesting readiness for strategic collaborations, milestone-driven deals, or equity-backed licensing arrangements to support expansion.

Operational Readiness Current tech stack and mid-sized team (51-200 employees) indicate a nimble organization with potential interest in CRO/CDMO partnerships, clinical development support, and scalable manufacturing arrangements to advance clinical programs.

Similar companies to Terns Pharmaceuticals

Terns Pharmaceuticals Tech Stack

Terns Pharmaceuticals uses 8 technology products and services including Amazon Web Services, Drupal, Squarespace, and more. Explore Terns Pharmaceuticals's tech stack below.

Media & News

Terns Pharmaceuticals's Email Address Formats

Terns Pharmaceuticals uses at least 3 email formats:
Terns Pharmaceuticals Email FormatsExamplePercentage
FLast@ternspharma.comJDoe@ternspharma.com
80%
Last@ternspharma.comDoe@ternspharma.com
19%
FirstL@ternspharma.comJohnD@ternspharma.com
1%

Frequently Asked Questions

What is Terns Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Terns Pharmaceuticals is a publicly traded company; the company's stock symbol is TERN.

What is Terns Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Terns Pharmaceuticals's official website is ternspharma.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Terns Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of October 2026, Terns Pharmaceuticals's annual revenue is estimated to be $50M - $100M.

What is Terns Pharmaceuticals's SIC code and NAICS code?

Minus sign iconPlus sign icon
Terns Pharmaceuticals's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Terns Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of October 2026, Terns Pharmaceuticals has approximately 61 employees across 3 continents, including North America, Asia and Europe. Key team members include Chief Executive Officer: S. S., Senior Executive Assistant To Cdoo, Cmo, & Cbo: M. S. R. and Vp, Head Of Research: C. J. Explore Terns Pharmaceuticals's employee directory with LeadIQ.

What industry does Terns Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Terns Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Terns Pharmaceuticals use?

Minus sign iconPlus sign icon
Terns Pharmaceuticals's tech stack includes Amazon Web Services, Drupal, Squarespace, Cookiebot, NetSuite, Microsoft 365, Smartsheet and Vimeo.

What is Terns Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Terns Pharmaceuticals's email format typically follows the pattern of FLast@ternspharma.com. Find more Terns Pharmaceuticals email formats with LeadIQ.

How much funding has Terns Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of October 2026, Terns Pharmaceuticals has raised $1.1B in funding. The last funding round occurred on Dec 09, 2025 for $150M.

When was Terns Pharmaceuticals founded?

Minus sign iconPlus sign icon
Terns Pharmaceuticals was founded in 2017.
Terns Pharmaceuticals logo

Terns Pharmaceuticals

Biotechnology ResearchCalifornia, United States51-200 Employees

Terns Pharmaceuticals is a mid-sized biotechnology company headquartered in Foster City, California. It is in the clinical stage of development, pursuing small-molecule candidates aimed at serious diseases, with a focus on oncology and obesity. Its pipeline includes clinical programs such as an allosteric BCR-ABL inhibitor and a GLP-1 receptor agonist, as well as a THR-β agonist. Preclinical programs target GIPR modulation.

In 2025, Terns presented positive Phase 1 data for its GLP-1 receptor agonist in obesity at the American Diabetes Association Scientific Sessions. These activities reflect the company's engagement with scientific forums as it advances therapies for cancer and metabolic diseases.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
TERN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $1.1B

    Terns Pharmaceuticals has raised a total of $1.1B of funding over 7 rounds. Their latest funding round was raised on Dec 09, 2025 in the amount of $150M as a Post IPO Equity.

  • $50M - $100M

    Terns Pharmaceuticals's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.